Key facts
- This page summarizes Angela Gill Nelms's Form 4 filing for RenovoRx, Inc. (RNXT).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 23 Jan 2024, 21:50.
Angela Gill Nelms - 19 Jan 2024 Form 4 Insider Report for RenovoRx, Inc. (RNXT)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- RNXT
- Reported as of
- 19 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 23 Jan 2024, 21:50:30 UTC
- Prior SEC filing
- 04 Oct 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Angela Gill Nelms
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Angela Gill Nelms filed Form 4 for RenovoRx, Inc. (RNXT) on 23 Jan 2024.
Change
- Previous filing in this sequence was filed on 04 Oct 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RNXT
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +33,768
- Change %
- Price
- $0.000000
- Shares after
- 33,768
- Date
- 19 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 33,768
- Exercise price
- $1.08
- Footnotes
- F1
RNXT
transaction
Derivative
Stock Option
Award
- Transaction value
- $0
- Shares
- +125,132
- Change %
- Price
- $0.000000
- Shares after
- 125,132
- Date
- 19 Jan 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 125,132
- Exercise price
- $1.08
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On January 19, 2024, the Reporting Person was awarded a stock bonus of 33,768 shares of common stock pursuant to the Company's 2021 Omnibus Equity Incentive Plan (the "Plan"). These shares were fully vested upon issuance to the Reporting Person, and expire on January 19, 2034.
Footnote F2
On January 19, 2024, the Reporting Person received a nonqualified stock option grant for a total of 125,132 shares of common stock vesting over four years at a rate of 1/48 per month with no cliff, beginning vesting on February 1, 2024. The option will become fully vested and exercisable on February 1, 2028, and expires on January, 19, 2034.